IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

INTEGRA LIFESCIENCES HOLDINGS CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$13.45+0.24 (+1.82%)

Close on Oct 19, 2026

Market cap: $1.05B
P/E (TTM): –
Dividend yield: –

INTEGRA LIFESCIENCES HOLDINGS CORP income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	1,635	1,611	1,542	1,558	1,542	1,372	1,518	1,472	1,188	992	883	797	697	831	780	732	682	655
Cost of Revenue	804	728	657	587	598	521	565	571	436	349	327	303	280	314	299	268	245	253
Gross Profit	832	882	885	970	945	851	953	901	753	643	556	494	417	516	481	464	438	402
Research & Development	99	115	104	101	93	77	80	78	63	58	51	44	43	51	51	48	44	60
Selling, General & Admin	700	717	657	616	637	595	688	691	624	456	416	376	332	373	358	305	281	281
Total Costs & Expenses	2,129	1,582	1,430	1,319	1,345	1,220	1,424	1,361	1,143	877	803	729	661	757	725	633	585	607
Operating Income	-493	28	112	239	197	151	94	111	45	115	80	68	35	74	55	99	98	47
Interest Expense	86	71	51	50	50	72	54	65	35	26	24	22	20	22	28	18	23	30
Interest & Investment Income	18	20	17	12	6.74	9.30	11	2.80	0.26	0.02	0.03	0.17	4.93	1.21	0.47	0.23	0.63	2.11
Other Non-Operating Income	-2.35	3.94	3.72	12	19	4.43	9.52	8.29	1.35	0.85	4.59	-0.49	-1.80	-0.72	0.76	1.55	-2.08	-0.91
Asset Impairment Charges	511	0	0	–	–	–	–	–	3.29	0	0.38	0.79	0.34	0	0	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	-2.29	0	0	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	0	0	0.64	42	0	0	-1.39	-6.99	-1.77	-0.48	-0.91	-1.97	-1.31	0	–	–	–
Pretax Income	-564	-18	81	214	215	94	60	57	11	90	61	46	19	52	28	82	73	19
Income Tax Expense	-47	-11	13	33	46	-40	9.90	-3.40	-53	16	54	9.27	-3.24	11	0.51	16	22	-9.19
Income from Continuing Operations	–	–	–	–	–	–	–	–	65	75	6.85	36	22	–	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	0	0	-10	-2.29	-43	–	–	–	–	–
Net Income	-516	-6.94	68	181	169	134	50	61	65	75	-3.52	34	-21	41	28	66	51	28
EPS (Basic)(per share)	-6.74	-0.09	0.85	2.18	2.00	1.58	0.59	0.73	0.84	1.00	-0.05	0.52	-0.37	0.73	0.49	1.11	0.88	0.49
EPS (Diluted)(per share)	-6.74	-0.09	0.84	2.16	1.98	1.57	0.58	0.72	0.82	0.94	-0.05	0.52	-0.37	0.72	0.48	1.09	0.87	0.48
Shares Outstanding (Basic, Weighted)(shares)	77	77	80	83	85	85	86	83	77	74	69	65	57	56	58	59	58	56
Shares Outstanding (Diluted, Weighted)(shares)	77	77	80	84	85	85	86	84	79	79	71	66	58	57	59	60	59	57
EBITDA	–	–	–	–	–	–	203	222	134	188	138	114	66	126	105	138	138	78

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 52.5%
Operating margin: 4.0%
Net margin: -0.4%
Return on equity, FY2025: -39.9%

Financial strength

Current ratio: 3.60
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 64.8%

Valuation

P/E ratio: –
Price to sales: 0.64
Price to book: 1.01
Dividend yield: –